Searchable abstracts of presentations at key conferences in endocrinology

ea0063p533 | Diabetes, Obesity and Metabolism 2 | ECE2019

A novel oral pyruvate dehydrogenase kinase 4 inhibitor ameliorates various spectrum of metabolic diseases in mice

Jeon Jae-Han , Lee In-Kyu , Choi Yeon-Kyung , Park Keun-Gyu , Kim Na-Young , Park Sung Don , Ahn Jin Hee , Kim Min-Ji

Pyruvate dehydrogenase kinase 4 (PDK4) activation is associated with metabolic diseases including hyperglycemia, insulin resistance, allergies, and cancer. We report here a new series of allosteric PDK4 inhibitor modified from hit anthraquinone. A novel PDK4 inhibitor, namely compound 8c, improved glucose tolerance in diet-induced obese mice. PDH activity in muscle and liver was enhance d by compound 8c treatment. Given the importance of PDK4 in immune cells including mast cel...